List of Excipients in Branded Drug CITANEST PLAIN

« Back to Dashboard

Generic Drugs Containing CITANEST PLAIN

Company	Ingredient	NDC	Excipient
Dentsply Pharmaceutical Inc	prilocaine hydrochloride	66312-630	HYDROCHLORIC ACID
Dentsply Pharmaceutical Inc	prilocaine hydrochloride	66312-630	SODIUM HYDROXIDE
Dentsply Pharmaceutical Inc	prilocaine hydrochloride	66312-630	WATER

What are the Most Frequently-Used Excipients in CITANEST PLAIN?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE
1	WATER

Citanest Plain Excipient Strategy and Commercial Opportunities

Last updated: October 16, 2026

Citanest Plain is a preservative-free, vasoconstrictor-free dental local anesthetic based on prilocaine hydrochloride. Its commercial value lies less in proprietary excipients than in a clean formulation platform: 4% prilocaine hydrochloride, sodium chloride for tonicity, and water for injection, with pH adjustment as required. The most credible opportunities are generic dental cartridges, preservative-free multidose or single-dose presentations, differentiated packaging, and regional products targeting patients for whom epinephrine-containing anesthetics are unsuitable.

What is Citanest Plain and how is it formulated?

Citanest Plain Dental is an injectable local anesthetic containing prilocaine hydrochloride at a concentration of 40 mg/mL. A standard 1.8 mL dental cartridge contains approximately 72 mg of prilocaine hydrochloride. The formulation does not contain epinephrine or another vasoconstrictor.

Public labeling identifies the principal formulation components as follows:

Component	Function	Approximate role
Prilocaine hydrochloride	Active local anesthetic	40 mg/mL
Sodium chloride	Tonicity adjustment	Approximately 6 mg/mL in the labeled formulation
Water for Injection	Vehicle	Quantity sufficient
Hydrochloric acid or sodium hydroxide	pH adjustment	Low concentration, process-dependent

The absence of methylparaben and other antimicrobial preservatives is commercially important. Dental cartridges are normally supplied as sterile, single-use units, which reduces the need for preservative systems. The formulation also avoids sulfite antioxidants that are commonly associated with epinephrine-containing local anesthetics.

Citanest Plain should be distinguished from Citanest Forte and other prilocaine products containing a vasoconstrictor. Citanest Plain is designed for situations in which prolonged soft-tissue anesthesia or reduced systemic absorption from epinephrine is not the primary objective.

What excipients protect the commercial identity of Citanest Plain?

The excipient system is simple and has limited patent value. The commercial identity is protected mainly through dosage form, container closure, sterility, manufacturing consistency, and dental workflow integration.

Sodium chloride

Sodium chloride provides isotonicity and supports injection tolerability. It is a low-risk, widely accepted pharmaceutical excipient with extensive regulatory precedent. A generic manufacturer would normally retain sodium chloride unless it can demonstrate equivalent tonicity and acceptable local tolerability with another system.

Potential development issues include:

• Osmolality control across the product shelf life.
• Compatibility with glass cartridges and elastomeric components.
• Avoidance of precipitation or pH drift.
• Consistent fill volume in small dental cartridges.
• Control of particulate matter.

Water for Injection

Water for Injection is the expected vehicle for an injectable dental anesthetic. Alternative nonaqueous vehicles would create unnecessary safety, regulatory, and manufacturing burdens and would not provide a clear commercial advantage.

pH adjustment

Prilocaine hydrochloride is formulated in an acidic aqueous environment to support chemical stability and solubility. A manufacturer may use hydrochloric acid and sodium hydroxide for pH adjustment. The exact adjustment process can remain confidential as manufacturing know-how, but it is unlikely to create meaningful product differentiation.

A development target should balance three factors:

1. Chemical stability of prilocaine.
2. Injection comfort.
3. Compatibility with sterilization and container components.

Raising pH can reduce injection discomfort in some local-anesthetic formulations, but excessive pH adjustment may increase precipitation risk and reduce shelf-life robustness. Any pH advantage would require comparative clinical or tolerability data to support a marketing claim.

What excipients are intentionally absent from Citanest Plain?

Citanest Plain’s main formulation advantage is what it excludes.

Excluded component	Commercial implication
Epinephrine	Suitable for cases where vasoconstrictor exposure is undesirable
Sulfite antioxidants	Avoids sulfite exposure associated with many epinephrine products
Methylparaben	Supports preservative-free positioning
Antimicrobial preservative	Appropriate for sterile single-use cartridges
Oil or cosolvent system	Maintains a conventional aqueous injectable profile

A preservative-free formulation may appeal to dental clinics seeking simple ingredient disclosure and to patients reporting sensitivity to preservatives or sulfites. The claim must remain precise. Absence of epinephrine does not make the product free of all adverse cardiovascular or hematologic risks.

Prilocaine itself has a recognized risk of methemoglobinemia, particularly at high doses, in susceptible patients, or when combined with other oxidizing agents. Excipient selection cannot eliminate that active-ingredient risk. Labeling, maximum-dose control, and cartridge identification remain central to product safety (U.S. Food and Drug Administration, n.d.-a).

How strong is the patent estate for Citanest Plain?

Citanest Plain has limited expected patent protection because prilocaine hydrochloride and conventional aqueous dental injection technology are mature.

Protection category	Expected strength
Prilocaine composition of matter	Expired or commercially irrelevant
Basic aqueous formulation	Low
Sodium chloride tonicity system	Very low
Preservative-free formulation	Low unless linked to a narrow technical effect
Dental cartridge presentation	Low to moderate, depending on device claims
Manufacturing process	Moderate only if process-specific and difficult to replicate
Brand and trade dress	Potentially meaningful
Regulatory exclusivity	Not expected to provide a current barrier for a legacy product

A follow-on applicant is more likely to encounter regulatory and technical requirements than a meaningful patent barrier. The strongest defensible assets would be:

• A validated low-particulate cartridge system.
• Improved container closure integrity.
• Extended room-temperature stability.
• Reduced extractables and leachables.
• A ready-to-use cartridge compatible with common dental aspirating syringes.
• A formulation with demonstrated injection-comfort or stability advantages.
• A proprietary manufacturing process that improves yield or reduces breakage.

An applicant should not rely on sodium chloride, water, or pH adjustment as a defensible patent position. Those elements are conventional and vulnerable to obviousness and prior-art challenges.

What is the FDA regulatory status of Citanest Plain?

Citanest Plain is an established prescription local anesthetic product. The key regulatory pathway for a competing product is generally an abbreviated new drug application if the reference product and dosage form are eligible for generic approval.

Relevant regulatory considerations include:

• Same active ingredient: prilocaine hydrochloride.
• Same route: local infiltration or nerve block injection.
• Same concentration: 4%, where matching the reference.
• Same dosage form: sterile injectable solution.
• Equivalent strength and labeling.
• Demonstrated sterility, particulate control, stability, and container compatibility.
• Comparative physicochemical characterization.
• Appropriate labeling for methemoglobinemia and local-anesthetic toxicity.

For sterile injectable generics, FDA review typically places substantial weight on chemistry, manufacturing, and controls. A product can be clinically familiar yet difficult to commercialize if cartridge filling, terminal sterilization, aseptic processing, or container-closure validation is weak.

The FDA Inactive Ingredient Database can support excipient precedent, but database presence does not replace product-specific safety, compatibility, and quality justification (U.S. Food and Drug Administration, n.d.-b).

What is the Orange Book status of Citanest Plain?

The Orange Book should be checked for the current status of the relevant Citanest Plain NDA, reference-listed drug designation, patents, and exclusivity codes. Legacy injectable products may appear as discontinued, withdrawn, or otherwise inactive products depending on the timing and reason for discontinuation.

For commercial planning, the critical questions are:

1. Whether a current reference-listed drug is available for ANDA comparison.
2. Whether the product is listed as discontinued for commercial reasons rather than safety or efficacy reasons.
3. Whether FDA has identified a suitable reference product or requires another regulatory route.
4. Whether any patents or exclusivity periods are listed against the relevant product.

A discontinued brand does not automatically create an open market. The absence of a currently marketed reference product can complicate ANDA development, reference-product sourcing, bioequivalence strategy, and launch timing (U.S. Food and Drug Administration, n.d.-c).

When does Citanest Plain lose exclusivity?

Citanest Plain’s active pharmaceutical ingredient is old, and any original composition-of-matter exclusivity has long expired. Current commercial exclusivity, if any, would depend on product-specific regulatory listings, patents, trademarks, contracts, or supply relationships rather than the prilocaine molecule.

The practical exclusivity timeline is therefore:

Asset	Commercial status
Prilocaine hydrochloride molecule	Generic and mature
Conventional 4% aqueous injection	Broad prior art
Preservative-free positioning	Generally difficult to monopolize
Citanest brand name	Trademark-based protection
Dental cartridge design	Potential device or packaging rights
Manufacturing process	Potential trade-secret protection
Market access	Dependent on regulatory pathway and supply reliability

No meaningful Paragraph IV opportunity should be assumed without confirming a current reference-listed drug and active Orange Book patent listing. If no listed patents remain, a generic applicant would not need to challenge an Orange Book patent through Paragraph IV. A Paragraph IV strategy would become relevant only if an active listed patent covers the reference product or an associated formulation or device.

What formulation patents could be pursued for a Citanest Plain successor?

A new excipient patent would need a technical result that is measurable and non-obvious. The most plausible claim areas are narrow.

Low-particulate injectable formulation

A formulation or process that reduces visible and subvisible particles could support a patent if the result depends on a specific pH range, excipient ratio, cartridge material, sterilization cycle, or filling process.

Extended stability

A patent may be possible for a composition that maintains assay, impurity profile, pH, and sterility over an extended period under defined storage conditions. A broad claim to prilocaine, sodium chloride, and water would likely be weak.

Container-closure compatibility

A system involving a specific glass type, stopper composition, coating, or cartridge seal could create defensible device or packaging claims. The commercial value would increase if the system reduces adsorption, leachables, breakage, or dose variability.

Alternative single-use packaging

Unit-dose polymer cartridges, prefilled dental syringes, or integrated delivery systems could provide stronger commercial differentiation than a reformulated vial. The relevant protection would likely combine formulation, container, and delivery-device claims.

What commercial opportunities exist for Citanest Plain excipients?

Generic 4% prilocaine dental cartridges

The most direct opportunity is a lower-cost generic that reproduces the established formulation and cartridge format. Dental practices value dependable supply, consistent cartridge performance, and compatibility with existing aspirating syringes.

Key purchasing criteria include:

• Low breakage rate.
• Reliable plunger movement.
• Clear solution and low particulate burden.
• Stable supply.
• Consistent labeling and packaging.
• Competitive price per cartridge.
• Availability through dental distributors.

Preservative-free injectable platform

The Citanest Plain formulation can support a broader platform for preservative-free local anesthetics. The same packaging, aseptic filling, and quality systems could support products containing other dental anesthetic actives, subject to regulatory requirements.

Potential platform products include:

• Lidocaine without epinephrine.
• Mepivacaine without vasoconstrictor.
• Prilocaine at alternative strengths.
• Hospital or specialty-use local anesthetic injections.

The platform economics improve when one cartridge line can handle multiple active ingredients and strengths without extensive equipment changes.

Premium ready-to-use presentation

A manufacturer could offer prefilled syringes or ergonomic cartridges designed to reduce preparation steps. The premium would need to be justified by:

• Lower chairside handling time.
• Better dose control.
• Reduced contamination risk.
• Improved inventory management.
• Compatibility with standard dental injection systems.

This model may be more attractive in hospitals, dental service organizations, and high-throughput clinics than in small independent practices.

Regional supply security

Prilocaine products can benefit from regional manufacturing and supply agreements where dental anesthetic shortages occur. A manufacturer with reliable sterile fill-finish capacity could pursue private-label, distributor, or government procurement contracts.

The main barrier is not excipient cost. It is sterile manufacturing capacity, validated cartridge supply, quality release, and regulatory maintenance across jurisdictions.

How does Citanest Plain compare with competing dental anesthetics?

Product type	Vasoconstrictor	Main commercial advantage	Main limitation
Citanest Plain, 4% prilocaine	No	Preservative-free, no epinephrine, high concentration	Methemoglobinemia risk; duration may be shorter than vasoconstrictor products
Lidocaine 2% plain	No	Familiar, broad generic supply	Lower concentration and often shorter duration
Mepivacaine 3% plain	No	Established vasoconstrictor-free dental option	Competitive generic pricing
Articaine with epinephrine	Yes	Strong diffusion and longer clinical duration	Epinephrine and sulfite exposure
Prilocaine with epinephrine	Yes	Longer duration than plain prilocaine	Loses the principal plain-formulation positioning

Citanest Plain competes on patient selection and formulation simplicity rather than maximum duration. A generic entrant should avoid positioning it as a universal replacement for epinephrine-containing anesthetics.

What manufacturing and intellectual-property barriers affect entry?

The active ingredient and excipients are accessible. The operational barriers are more significant.

Sterile cartridge production

Dental cartridges require specialized filling, sealing, inspection, and packaging. Defects can include underfill, chipped glass, stopper movement, leakage, and cosmetic particulate contamination.

Extractables and leachables

The product is stored in direct contact with glass, elastomer, adhesive, and packaging materials. A new cartridge or polymer system requires extractables and leachables assessment under ICH and FDA expectations.

Sterilization

The selected sterilization approach must preserve prilocaine potency, limit degradants, and maintain container integrity. Terminal sterilization may simplify sterility assurance but can impose thermal or radiation stress. Aseptic processing raises facility and validation requirements.

Supply chain

A commercially viable product needs qualified sources for:

• Prilocaine hydrochloride.
• Pharmaceutical-grade sodium chloride.
• Glass or polymer cartridges.
• Elastomeric plungers and seals.
• Sterile packaging materials.

The highest practical risk may be cartridge availability rather than excipient availability.

Which companies are likely to challenge or supply the market?

Competition is likely to come from three groups:

1. Established dental anesthetic manufacturers with existing cartridge lines.
2. Generic injectable manufacturers with sterile fill-finish capacity.
3. Regional dental suppliers using contract manufacturing or private-label arrangements.

The strongest competitor is not necessarily the company with the lowest API cost. It is the manufacturer that can maintain uninterrupted cartridge supply, satisfy local regulatory requirements, and secure dental distributor access.

Licensing opportunities are most credible for:

• Regional marketing rights.
• Contract manufacturing.
• Private-label dental cartridges.
• Cartridge technology.
• Sterile fill-finish capacity.
• Combination portfolios covering prilocaine, lidocaine, and mepivacaine.

No specific current licensing transaction should be assumed without transaction-level verification. The product’s age and conventional formulation make manufacturing and distribution agreements more commercially likely than active-ingredient licensing.

What generic launch scenarios exist for Citanest Plain?

Scenario	Market effect	Main requirement
Full generic substitution	Price reduction and broader supply	Approved reference pathway and reliable cartridge production
Brand revival or relaunch	Premium for recognized name	Trademark rights, supply restoration, distributor support
Private-label launch	Faster channel penetration	Contract manufacturing and regional approvals
Premium prefilled format	Higher gross margin	Device development and workflow evidence
Multi-product dental portfolio	Lower selling cost per account	Shared manufacturing and sales infrastructure
Regional shortage response	Short-term pricing opportunity	Rapid regulatory and supply execution

A plain-prilocaine generic is most attractive where the reference product is unavailable, supply is constrained, or dental practices need a non-epinephrine option. A premium strategy requires more than the same excipients. It needs a delivery, packaging, stability, or supply-chain advantage.

Key Takeaways

• Citanest Plain is a 4% prilocaine hydrochloride sterile dental injection without epinephrine.
• Its core excipients are sodium chloride and Water for Injection, with pH adjustment.
• The excipient composition has low standalone patent strength.
• Commercial defensibility is more likely to come from cartridges, sterility systems, stability, packaging, and supply reliability.
• The primary generic opportunity is a preservative-free 4% prilocaine dental cartridge.
• A prefilled or ergonomically improved delivery system could support premium pricing.
• Prilocaine’s methemoglobinemia risk remains a central labeling and risk-management issue.
• Orange Book, reference-product, patent, and exclusivity status must be verified before selecting an ANDA or alternative regulatory pathway.
• The strongest licensing opportunities involve regional distribution, private label, contract manufacturing, and sterile cartridge technology.
• Manufacturing execution is likely to be a greater entry barrier than excipient access.

FAQs

Is Citanest Plain preservative-free?

Yes. The labeled formulation is an aqueous prilocaine hydrochloride injection using sodium chloride and Water for Injection, without a conventional antimicrobial preservative.

Does Citanest Plain contain epinephrine?

No. Citanest Plain is the plain formulation and does not contain epinephrine or another vasoconstrictor.

Can sodium chloride be removed from a generic Citanest Plain formulation?

It can be replaced only if the alternative formulation demonstrates acceptable tonicity, stability, compatibility, injection tolerability, and regulatory equivalence. Retaining sodium chloride is the lower-risk development strategy.

Is prilocaine hydrochloride protected by an active composition patent?

Prilocaine hydrochloride is a mature active ingredient. Any current protection would more likely involve a specific product, device, formulation, process, trademark, or regulatory listing than the basic molecule.

What is the most valuable improvement over the legacy Citanest Plain formulation?

The strongest opportunities are improved cartridge integrity, reduced particulate contamination, longer validated shelf life, reliable supply, and a ready-to-use delivery format. A minor excipient substitution alone is unlikely to support premium commercial value.

References

1. Dentsply Pharmaceutical. (n.d.). Citanest Plain Dental: Prilocaine hydrochloride injection, 4% prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Prilocaine hydrochloride injection labeling and safety information. FDA. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (n.d.-b). Inactive Ingredient Database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

5. United States Pharmacopeia. (2024). General chapter <1>: Injections and implanted drug products, product quality tests. U.S. Pharmacopeial Convention.

6. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH. https://www.ich.org/page/quality-guidelines